BioFrontier Venture Syndicate

What It Is

BioFrontier Syndicate gives accredited investors direct access to individual frontier therapeutics deals at the intersection of technology and biology. Curated by Luca Giani, AV Senior Principal and 3x biotech founder, each opportunity comes with a full investment memo, founder access, and co-investment alongside leading biotech and deep-tech VCs. No fund commitment required. Free to invest or pass on each deal.

Who Might be Interested

Investors who want deal-by-deal exposure to biotech and the intersection of technology and biology without a full fund commitment, operators, scientists, and founders who want to back what they know, family offices building a direct position in frontier therapeutics, and AV investors looking to go deeper beyond their fund allocation.

Why Now

Pharma faces roughly $300 billion in patent expirations by 2030 and cannot R&D its way out of it. At the same time, venture capital has rotated toward later-stage, de-risked assets: mega-rounds above $100M now represent 66% of all biopharma VC deployed, up from 35% pre-pandemic. The result is a structural dislocation. The companies that will define tomorrow’s acquisitions are being built today, at prices that reflect the market’s impatience rather than their long-term strategic value. For investors who can underwrite the potential that science offers, the entry point rarely looks better than it does right now.

Take 5 seconds. No document uploads.

It’s All About Access to Cutting-Edge Deals

You Get Access to Deals Led by Brand Name VC Firms: Quality, Quantity, Diversification.

Co-investors shown for illustrative purposes only, are not indicative of all organizations with which AV co-investors, and do not necessarily indicate future co-investors. The identity of a co-investor is not a guarantee of investment quality or performance.

Take 5 seconds. No document uploads.

About Alumni Ventures

Explore our full Trophy Room of awards and recognition.

*Performance data is from Cambridge Associates Venture Benchmarks and is as of 06/30/25. Industry Top Quartile as determined by Cambridge Associates. Distributions to Paid-In Capital (DPI) for AV Funds and Industry Top Quartile is net of management fees and net of incentive allocations applied to amounts distributed to investors. For additional information on Cambridge Associates and the data and calculations see av-funds.com/disclosures.

BioFrontier Content

Content at the intersection of entrepreneurship, venture capital, and our shared interests.

Sample Deals

We invest alongside other established venture firms in a broad range of companies to help build you a diversified portfolio.

*For illustration purposes only. These investments are not intended to suggest any level of investment returns. No representation is intended that any outcome discussed is or would be representative of outcomes experienced by any AV fund or investor. Many returns in investments result in the loss of capital invested. These investments are not available to future fund investors except potentially in certain follow-on investment options.

Interested in Seeing Elite Venture Deals?